The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; MDACC Cancer Center Support Grant; NIH/NCI award number CA016672; Novartis; Numab; Nurix; Oncternal Therapeutics, Inc; Pharmacyclics; Xencor
 
Ryan Jacobs
Consulting or Advisory Role - Abbvie; AstraZeneca; Pharmacyclics; Verastem
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Janssen; Pharmacyclics
Research Funding - MEI Pharma; Pharmacyclics; Teneobio; TG Therapeutics
 
Paul M. Barr
Consulting or Advisory Role - AbbVie; AstraZeneca; Bristol-Myers Squibb; Celgene; Genentech; Gilead Sciences; Janssen; MEI Pharma; Merck; Morphosys; Pharmacyclics LLC, an AbbVie Compan; Seagen; TG therapeutics
Research Funding - AstraZeneca; TG therapeutics
 
John N. Allan
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Epizyme; Genentech; Janssen; Pharmacyclics; TG Therapeutics
Speakers' Bureau - Abbvie; BeiGene; Janssen; Pharmacyclics
Research Funding - BeiGene; Celgene; Genentech; Janssen; TG Therapeutics
 
Tanya Siddiqi
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Kite, a Gilead company
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene
Research Funding - Acerta Pharma (Inst); Ascentage Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
 
Alessandra Tedeschi
Consulting or Advisory Role - Abbvie; AstraZeneca; Beigene; Janssen
Speakers' Bureau - Abbvie; AstraZeneca; Beigene; Janssen
 
Thomas J. Kipps
Employment - Moores Cancer Center
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc
Honoraria - Abbvie; AstraZeneca; Dava Oncology; Genentech; Janssen; Pharmacyclics
Consulting or Advisory Role - Abbvie; Dava Oncology; Genentech; Janssen; Pharmacyclics
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Pharmacyclics/Janssen; Verastem/Pharmacyclics
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Leukemia and Lymphoma Society (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst)
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst)
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; AstraZeneca; Dava Oncology; Genentech/Roche; Janssen
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Amgen; Caribou Biosciences; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen; Pfizer; Pharmacyclics; Secura Bio; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Amgen; Caribou Biosciences; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Secura Bio; TG Therapeutics; Vaniam Group
Research Funding - Caribou Biosciences (Inst); MustangBio (Inst); Nurix (Inst); Pharmacyclics (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie/Genentech; Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Xavier C. Badoux
Honoraria - Abbvie; Janssen
Travel, Accommodations, Expenses - Abbvie
 
Andrea Visentin
Consulting or Advisory Role - AbbVie; AstraZeneca; BeiGene; CSL Behring; JJ Innovative Medicine; Takeda
Research Funding - Abbvie; AstraZeneca; BeiGene; CSL Behring; JJ Innovative Medicine; Takeda
 
Masa Lasica
No Relationships to Disclose
 
Dennis Carney
No Relationships to Disclose
 
Anna Elinder Camburn
No Relationships to Disclose
 
Javier De La Serna Torroba
Consulting or Advisory Role - AbbVie; AstraZeneca; Janssen
Speakers' Bureau - AbbVie; AstraZeneca; Janssen
Travel, Accommodations, Expenses - Abbvie; AstraZeneca
 
Edith Szafer-Glusman
Employment - AbbVie
Stock and Other Ownership Interests - Abbvie
 
Cathy Zhou
Employment - Abbvie
Stock and Other Ownership Interests - AbbVie
 
Anita Szoke
Employment - AbbVie
Stock and Other Ownership Interests - AbbVie; Bristol-Myers Squibb
 
James P. Dean
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Paolo Ghia
Honoraria - Abbvie; AstraZeneca; BeiGene; Galapagos NV; Gilead Sciences; Janssen Oncology; Juno/Celgene/Bristol-Myers Squibb; Lilly; MSD; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene/Juno; Galapagos NV; Galapagos NV; Janssen; Lilly; MSD; Roche
Research Funding - Abbvie; AstraZeneca; Bristol-Myers Squibb/Celgene/Juno (Inst); Janssen Oncology
 
Constantine S. Tam
Honoraria - Abbvie; Beigene; Janssen-Cilag; Loxo/Lilly; Novartis; Pharmacyclics; Roche/Genentech
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen-Cilag (Inst)